AIDS: Research data from Dupont's 006 study was presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The study compares the non-nucleoside Sustiva (efavirenz) combined with Retrovir (ziduvodine, AZT) and Epivir (lamivudine, 3TC) against the protease inhibitor Crixivan with Retrovir and Epivir. Data was reviewed to determine Sustiva's efficacy, tolerability, and durability of virologic response. The 72-week data showed the Sustiva triple regimen to be more effective than the Crixivan triple regimen. Details of the study are provided.